Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies. * Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio(R)(inclisiran) vs. bempedoic acid in achieving LDL-C goals * New AZALEA-TIMI 71 analyses will further characterize the bleeding profile of abelacimab in patients with atrial fibrillation, including recurrent bleeding events * Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice Basel, August 19, 2026 - Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk. "The data we are presenting at this year's ESC Congress underscore our commitment to advancing cardiovascular science for patients who remain at risk despite current treatment," said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. "From foundational medicines Leqvio and Entresto to promising investigational therapies, our portfolio reflects our focus on addressing persistent challenges in cardiovascular care." Key abstracts accepted by ESC include: | Medicine/Disease | / | Abstract Title | / | Presentation Details | | Leqvio(R) | / | Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial | / | Tripoli (Hall B1) Late-Breaking Oral Presentation August 31, 08:15-08:30 CEST | | Leqvio(R) | / | An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial | / | Exchange Circle 3 (Research Gateway - Hall A1) ePoster August 29, 09:15-10:00 CEST | | Abelacimab | / | Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA-TIMI71 | / | Science Box 2 (Research Gateway - Hall A1) Oral Presentation August 29, 09:30-10:30 CEST | | Lipoprotein (a) [Lp(a)] | / | Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis | / | Exchange Circle 6 (Research Gateway - Hall A1) ePoster August 29, 16:15-17:00 CEST | | Entresto(R) | / | Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial | / | Station 5 (Research Gateway - Hall A1) ePoster August 31, 09:15-10:00 CEST | | Pacibekitug | / | TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk | / | Munich (Main Auditorium-Hall B3) Hot Line August 29, 08:45-09:00 CEST | About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing the boundaries of what's possible so more people can live longer, healthier lives. Building on our 40-year legacy, we're committed to shaping what's next in cardiovascular care through bold science and a diverse, industry-leading pipeline. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: [email protected]

Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent. By Thomson Reuters Aug 13, 2026 | 8:56 AM LONDON, Aug 13 (Reuters) - Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthcare which was planning a generic rival. The ruling is a boost for Novartis as it navigates a busy period of patent expiries including for Entresto, which makes up about 10% of Novartis' sales. Novartis' European patent for Entresto, which treats heart failure and can also treat hypertension, expired in 2023 though it still has a so-called supplementary protection certificate which does not expire until 2028. Accord applied to the High Court for a ruling that Novartis' patent had always been invalid, while Novartis counterclaimed over the threatened infringement of its patent, with Accord intending to launch a competing product later this year. Judge Richard Meade said that "all the attacks on the patent fail". He ruled that Novartis' patent was valid while in force, its supplementary protection certificate was also valid and that Accord's intended product would infringe it. Novartis and Accord did not immediately respond to requests for comment. Meade also said that Novartis' patent was separately held to be valid after legal proceedings in the Netherlands. The company last year lost a bid in the United States to block a generic version of Entresto. (Reporting by Sam Tobin; Editing by Susan Fenton)